Hypertension Classification — ESC/AHA 2018
| Category | Systolic (mmHg) | Diastolic (mmHg) | Action |
| Normal | < 120 | < 80 | Reassure, lifestyle promotion |
| Elevated | 120–129 | < 80 | Lifestyle changes, recheck in 3–6 months |
| Stage 1 | 130–139 | 80–89 | Lifestyle + consider drug if high CV risk/comorbidity |
| Stage 2 | ≥ 140 | ≥ 90 | Lifestyle + antihypertensive medication |
| Hypertensive Crisis | ≥ 180 | ≥ 120 | Immediate assessment: urgency vs emergency |
- Patient seated quietly for 5 minutes before measurement
- Correct cuff size: bladder encircles 80% of arm circumference
- Arm supported at heart level (mid-sternal notch)
- No caffeine or tobacco 30 minutes prior
- Bladder empty; patient not speaking during measurement
- Back supported; feet flat on floor; legs uncrossed
- Take two measurements 1–2 min apart; record average
- Bilateral arm measurement at initial assessment — use arm with higher reading
- Document time, arm used, position, and device used
Difference >20 mmHg between arms may indicate subclavian stenosis or coarctation — investigate further.
- White coat hypertension: Elevated in clinic, normal on ABPM (<135/85 awake) — lower CV risk, lifestyle advice only
- Masked hypertension: Normal in clinic, elevated on ABPM — higher CV risk, treat as sustained HTN
- Nocturnal dipping: Normal BP drops 10–20% at night. Non-dipping associated with end-organ damage and increased CV events
- ABPM daytime threshold: ≥135/85 mmHg
- ABPM night-time threshold: ≥120/70 mmHg
- ABPM 24-hour threshold: ≥130/80 mmHg
Indication for ABPM: suspected white coat/masked HTN, evaluating nocturnal dipping, assessing treatment efficacy, Ramadan medication management.
- Use validated upper-arm automated device (BHS/ESH validated list)
- Measure morning (before medication) and evening for 7 days
- Discard first day; average remaining readings
- Target home BP: <135/85 mmHg
- Provide structured BP diary or app (e.g., British Heart Foundation BP tracker)
- Instruct not to adjust medications based on single readings
- Wrist monitors not preferred — less accurate unless arm raised to heart level
| System | Investigation | Finding |
|---|
| Eyes | Fundoscopy | AV nipping, papilloedema, haemorrhages |
| Heart | ECG / Echocardiogram | LVH, strain pattern, diastolic dysfunction |
| Kidney | Creatinine / eGFR | CKD, reduced filtration |
| Kidney | UACR | Microalbuminuria >3 mg/mmol |
| Vasculature | Ankle-Brachial Index | PAD, <0.9 abnormal |
| Brain | History / MRI | Lacunar infarcts, white matter changes |
Pseudo-Resistance
- Poor medication adherence
- White coat effect
- Incorrect BP technique
- Inadequate doses
Drug/Lifestyle Causes
- NSAIDs, OCP, corticosteroids
- Excessive salt intake
- Obesity / OSAS
- Excessive alcohol
Secondary Causes
- Obstructive sleep apnoea (OSAS)
- Renal artery stenosis
- Primary hyperaldosteronism (Conn's)
- Phaeochromocytoma
- Cushing's syndrome
- Coarctation of aorta
Evidence-Based Lifestyle Interventions
Combined lifestyle changes can reduce systolic BP by 20–30 mmHg — comparable to one antihypertensive agent. These interventions reduce CV risk independently of BP effects.
- Fruits and vegetables: 4–5 servings/day each
- Low-fat dairy products: 2–3 servings/day
- Whole grains: 6–8 servings/day
- Lean meats, poultry, fish: ≤6 oz/day
- Nuts, seeds, legumes: 4–5 servings/week
- Reduced saturated fat and total fat
- Sweets and added sugars: ≤5 servings/week
Evidence: DASH trial showed 11.4 mmHg systolic reduction in hypertensive patients. Enhanced DASH + sodium restriction = 20+ mmHg reduction.
Evidence: 5–7 mmHg systolic reduction
| High-Sodium Foods (GCC Context) | Sodium Content |
|---|
| Processed/canned cheese (labneh blocks) | 400–600 mg/30g |
| Canned foul medames / chickpeas | 300–500 mg/100g |
| Pickles / mixed torshi | 800–1200 mg/100g |
| Salty crackers / chips (popular snacks) | 400–700 mg/30g |
| Cured/salted fish (fasikh, dried shrimp) | 1000+ mg/100g |
| Stock cubes / seasoning sachets | 800–1000 mg/cube |
Practical tip: Teach patients to read labels — target <600 mg Na per 100g. Avoid adding salt at table.
- 1 mmHg reduction per 1 kg weight lost
- Target BMI: 18.5–24.9 kg/m²
- Waist circumference: <102 cm (M), <88 cm (F)
- 10 kg weight loss → ~10 mmHg systolic reduction
- Refer to dietitian for structured plan
- Mediterranean or DASH diet patterns preferred
- 150 min/week moderate intensity aerobic exercise
- 5–7 mmHg systolic reduction
- Examples: brisk walking, swimming, cycling, Zumba
- 30 min sessions, 5 days/week minimum
- Resistance training: additional 2 days/week
- Avoid high-intensity exercise until BP controlled
- Encourage evening walks (cooler temperature in GCC)
- Increase potassium intake to 3.5–5g/day
- Counteracts sodium-induced hypertension
- High-K foods: bananas, dates, avocado, potatoes, lentils, spinach
- Magnesium and calcium also beneficial (dairy, nuts, seeds)
- Avoid K+ supplements without monitoring in CKD/ACEi/ARB users
- Alcohol: <14 units/week (men), <8 units/week (women)
- Reducing alcohol: 3–4 mmHg systolic reduction
- Smoking: does not directly cause sustained HTN but significantly increases CV risk
- Smoking cessation is the single most important CV risk modification
- Refer to smoking cessation programmes (NRT, varenicline)
- Note: Alcohol less prevalent in GCC — shisha/hookah smoking common
- Chronic stress activates RAAS and SNS — sustained BP elevation
- Mindfulness-based stress reduction (MBSR): 4–5 mmHg reduction
- Diaphragmatic breathing exercises (device-guided respiration: RESPeRATE)
- Sleep quality: target 7–8 hours/night
- OSAS screening if obese, snoring, daytime sleepiness (Epworth >10)
- CPAP for OSAS reduces SBP by 2–3 mmHg
- Limit screen time before bed; consistent sleep schedule
- Validated Arabic BP diary for home monitoring
- My Heart BP app (bilingual Arabic/English)
- WeightWatchers / Noom (Arabic interface)
- WHO HEARTS patient education leaflets (Arabic)
- DHA and MOH Saudi patient education portals
- Heart UK dietary advice (Arabic translations available)
- Measure BP app (validated by World Hypertension League)
- Engage family members — shared meal planning crucial in GCC households
Antihypertensive Drug Classes — Nursing Reference
First-line combination for most patients: ACEi or ARB + CCB (amlodipine) ± thiazide diuretic. Titrate to lowest effective dose before adding agents.
RamiprilPerindoprilLisinoprilEnalapril
Mechanism: Block conversion of angiotensin I → II (RAAS inhibition)
| Side Effects | Monitoring |
|---|
| Dry cough (10–20% — switch to ARB) | K+ (hyperkalaemia risk) |
| Angioedema (rare, stop immediately) | Creatinine/eGFR (AKI risk) |
| First-dose hypotension | BP 1–2 weeks after starting |
CONTRAINDICATED in pregnancy (teratogenic — oligohydramnios, renal dysplasia). Stop if pregnancy confirmed. Bilateral renal artery stenosis — avoid.
Preferred in: CKD with proteinuria, HFrEF, post-MI, diabetes with microalbuminuria
LosartanOlmesartanValsartanCandesartanIrbesartan
Use when ACEi not tolerated (cough, angioedema). Same renal/cardiac indications.
| Side Effects | Key Points |
|---|
| Hyperkalaemia | Do NOT combine with ACEi (dual RAAS blockade — increased AKI/hyperkalaemia risk) |
| AKI (same risk as ACEi) | Olmesartan: rare sprue-like enteropathy |
| Dizziness / first-dose hypotension | CONTRAINDICATED in pregnancy |
AmlodipineFelodipineDiltiazemVerapamil
| Type | Examples | Key Side Effects |
|---|
| Dihydropyridine (DHP) | Amlodipine, Felodipine | Peripheral oedema (ankle), headache, flushing — can be combined with beta-blockers |
| Non-DHP | Diltiazem, Verapamil | Bradycardia, heart block, constipation — avoid with beta-blockers |
Amlodipine is the preferred CCB — longest half-life, once daily, well tolerated. Peripheral oedema managed by elevating legs (not diuretics unless also hypertensive).
IndapamideBendroflumethiazideChlortalidone
Preferred: Indapamide (lower metabolic side effects than older thiazides)
| Side Effect | Monitoring / Action |
|---|
| Hyponatraemia | U&E at baseline, 1 month, then 6-monthly |
| Hypokalaemia | Supplement K+ if <3.5, consider amiloride |
| Hyperuricaemia / gout flares | Avoid in gout history — use alternative |
| Postural hypotension (elderly) | Review in hot GCC summers — dehydration risk |
BisoprololAtenololMetoprololCarvedilol
Use when: HFrEF, post-MI, angina, AF rate control, or anxiety-related HTN
| Contraindications | Side Effects |
|---|
| Asthma / severe COPD | Fatigue, cold extremities |
| 2nd/3rd degree AV block | Bradycardia, erectile dysfunction |
| Cardiogenic shock | Masks hypoglycaemia symptoms |
Do NOT abruptly stop beta-blockers — rebound hypertension and angina risk. Wean over 2–4 weeks.
Spironolactone 25–100mg
Indication: Resistant hypertension (4th agent), primary hyperaldosteronism (Conn's syndrome)
- Hyperkalaemia — monitor K+ closely, especially with ACEi/ARB (avoid combination if eGFR <45)
- Gynaecomastia / breast tenderness in men — switch to eplerenone
- Menstrual irregularities in women
- Renal function monitoring (creatinine/eGFR)
Stop if K+ >5.5 mmol/L or creatinine rises >30% from baseline.
DoxazosinPrazosin
- 4th-line agent in resistant hypertension
- Benefit in BPH (improves urinary symptoms)
- Postural hypotension — particularly first dose; advise to take at bedtime
- Avoid in stress urinary incontinence
- Modified-release doxazosin preferred to reduce postural hypotension
| Step | Treatment |
|---|
| Step 1 | ACEi (or ARB) + CCB (amlodipine) |
| Step 2 | ACEi/ARB + CCB + Thiazide diuretic |
| Step 3 | Above triple therapy at optimal doses |
| Step 4 (Resistant) | Add spironolactone 25mg, or doxazosin, or beta-blocker — refer to specialist |
Hypertensive Urgency vs Emergency
Hypertensive URGENCY — BP ≥180/120 mmHg
NO evidence of acute target organ damage
- Asymptomatic or mild headache
- No papilloedema, no focal neurology
- No chest pain, normal troponin
- Normal creatinine/urinalysis
Management:
- Oral antihypertensives — no IV required
- Oral amlodipine 5–10mg, labetalol 200mg, or captopril 25mg
- Target: reduce BP by max 25% over 24–48 hours
- Avoid rapid IV reduction — risk of ischaemic stroke/MI
- Outpatient review within 24–72 hours
- Review medication adherence and triggers
Hypertensive EMERGENCY — BP ≥180/120 mmHg
WITH acute target organ damage (TOD)
- Hypertensive encephalopathy (confusion, seizures)
- Acute kidney injury (rising creatinine, haematuria)
- Acute coronary syndrome (chest pain, ECG changes)
- Acute pulmonary oedema
- Aortic dissection (tearing pain, pulse deficit)
- Ischaemic or haemorrhagic stroke
- Eclampsia / pre-eclampsia with severe features
Management:
- ICU admission — IV antihypertensives
- Reduce 10–20% in first hour
- Reduce 15–25% over next 23 hours
- Arterial line for continuous BP monitoring
- EXCEPTION: Aortic dissection — target SBP <120 within 20 min
IV Agents by Emergency Type
| Emergency Type | Preferred IV Agent | Dose / Route | Notes |
| Hypertensive encephalopathy | Labetalol, Nicardipine | Labetalol 20mg IV bolus, then infusion | Avoid vasodilators alone — can worsen cerebral oedema |
| Acute Pulmonary Oedema (APO) | GTN (glyceryl trinitrate) | GTN infusion 10–200 mcg/min IV | Reduces preload + afterload; furosemide for diuresis |
| Aortic Dissection | Labetalol or Esmolol + SNP | Target SBP <120 within 20 min | Beta-blocker FIRST to reduce dP/dt, then vasodilator |
| ACS / NSTEMI | GTN infusion | 10–200 mcg/min IV | Avoid in right ventricular infarction |
| Ischaemic Stroke (pre-thrombolysis) | Labetalol | 10–20 mg IV | Target <185/110 for thrombolysis eligibility |
| Haemorrhagic Stroke | Nicardipine, Labetalol | Nicardipine infusion 5–15 mg/h | Target SBP <140 within 1 hour (AHA 2022) |
| Eclampsia | Hydralazine, Labetalol | Hydralazine 5–10mg IV bolus | MgSO4 for seizure prophylaxis; urgent delivery planning |
| Phaeochromocytoma crisis | Phentolamine | 5–15 mg IV bolus | Alpha-blockade FIRST; beta-blocker only after alpha established |
| Renal Crisis (scleroderma) | ACEi (captopril IV) | Variable | Exception where ACEi is preferred acutely |
Nursing Monitoring Protocol — Hypertensive Emergency
- Arterial line — continuous BP monitoring
- 12-lead ECG on admission, repeat if symptoms
- Cardiac monitoring (telemetry)
- Targeted BP goals — document clearly
- Avoid hypotension — target SBP not <100
- Hourly urine output (IDC) — target >0.5 ml/kg/h
- Strict fluid balance chart
- U&E, creatinine 4-hourly initially
- UACR/urinalysis for haematuria, casts
- Weigh daily if APO / fluid overload
- Hourly GCS assessment
- Pupil assessment with neuro obs
- Fundoscopy for papilloedema
- Seizure precautions
- CT head if sudden deterioration
- NIHSS score if stroke suspected
Secondary Hypertension — Causes, Investigation & Management
Secondary hypertension accounts for 5–10% of all hypertension but should be suspected in: young patients, resistant HTN, sudden onset, or clinical clues of underlying disease.
Most common secondary cause — CKD of any aetiology
- Mechanism: sodium retention, RAAS activation, reduced renal prostaglandins
- Investigation: eGFR, UACR, renal ultrasound, ANA/ANCA if vasculitis suspected
- Management: ACEi or ARB first-line (renoprotective — reduce proteinuria)
- Target BP: <130/80 if proteinuria (UACR >70 mg/mmol)
- Loop diuretics preferred over thiazides in advanced CKD (eGFR <30)
Bilateral renal artery stenosis: ACEi/ARB CONTRAINDICATED — acute bilateral ischaemia risk. Check creatinine rise >30% after starting — investigate for RAS.
Most common surgically correctable cause
- Classic triad: hypertension + hypokalaemia + metabolic alkalosis
- Symptoms: muscle weakness, cramps, polyuria, nocturia
- Screening: Aldosterone:Renin Ratio (ARR) — ARR >30 is significant
- Confirm: Salt loading test or fludrocortisone suppression test
- Localisation: CT adrenals — adenoma vs bilateral hyperplasia
- Adrenal vein sampling if CT inconclusive and surgery considered
- Unilateral adenoma → laparoscopic adrenalectomy (curative)
- Bilateral hyperplasia → spironolactone or eplerenone
"10% tumour" — 10% bilateral, 10% malignant, 10% extra-adrenal
- Classic triad: episodic headache + sweating + palpitations (paroxysmal hypertension)
- Hypertensive episodes triggered by: surgery, trauma, micturition (bladder pheo)
- Investigation: 24-hour urinary catecholamines / metanephrines; plasma fractionated metanephrines (preferred)
- Localisation: CT/MRI adrenals; MIBG scintigraphy for extra-adrenal
- Pre-op preparation: Alpha-blockade FIRST (phenoxybenzamine or doxazosin) for minimum 10–14 days
- Beta-blockade only AFTER alpha established (unopposed alpha = hypertensive crisis)
- High-salt, high-fluid diet to expand contracted plasma volume pre-op
- Surgery: laparoscopic adrenalectomy
NEVER give beta-blocker before alpha-blocker in phaeochromocytoma — risk of severe hypertensive crisis from unopposed alpha stimulation.
Cortisol excess — endogenous or exogenous (steroid use)
- Features: central obesity, moon face, buffalo hump, purple striae, easy bruising, proximal myopathy, skin thinning, diabetes
- Screening: overnight 1mg dexamethasone suppression test (cortisol >50 nmol/L = abnormal), 24h urinary free cortisol, late-night salivary cortisol
- ACTH levels differentiate pituitary (Cushing's disease) vs adrenal vs ectopic source
- Treatment: surgical removal of causative tumour (pituitary, adrenal or ectopic)
- Exogenous Cushing's: minimise steroid dose, consider steroid-sparing agents
- Narrowing of descending aorta (typically distal to left subclavian)
- Clinical clue: Radio-femoral pulse delay (femoral pulse delayed compared to radial)
- BP difference: upper arms higher than lower limbs (>20 mmHg difference)
- Rib notching on CXR (collateral intercostal arteries)
- Investigation: echo, CT angiography, MRI aorta
- Treatment: balloon angioplasty or surgical repair
- Commonly associated with bicuspid aortic valve
- Highly prevalent in GCC (obesity, lifestyle factors)
- Mechanism: intermittent hypoxia → sympathetic activation → sustained HTN
- Particularly associated with non-dipping BP pattern
- Screening: Epworth Sleepiness Scale >10, STOP-BANG questionnaire
- Investigation: overnight polysomnography (gold standard), home sleep test
- AHI >30 = severe OSAS
- Treatment: CPAP — reduces SBP by 2–3 mmHg (more in severe OSAS)
- Weight loss most effective intervention for OSAS resolution
Hypertension in the GCC — Epidemiology, Culture & Practice
GCC countries have among the highest hypertension prevalence globally — 45–50% of adults, largely undiagnosed and uncontrolled.
| Country | Prevalence | Control Rate |
|---|
| Saudi Arabia | ~46% | <20% adequately controlled |
| UAE | ~40% | ~30% aware and treated |
| Kuwait | ~33% | Underdiagnosed in younger adults |
| Bahrain / Qatar / Oman | 30–45% | National programmes expanding |
- Only ~50% of those with hypertension in Saudi Arabia are aware of their diagnosis
- High rates of secondary prevention gap — patients on treatment but uncontrolled
- Expat population: may have different health-seeking behaviour and insurance coverage
GCC dietary sodium intake often exceeds 12–15g NaCl/day (WHO target: <5g)
| Food Item | Sodium Risk | Nursing Advice |
|---|
| Processed cheese (triangle cheese, labneh blocks) | Very High | Use fresh labneh; limit to 1 serving/day |
| Canned foul, hummus, lentils | High | Choose no-added-salt versions; rinse canned beans |
| Pickles (mixed, turnip, olive) | Very High | Limit to small servings; make fresh at home |
| Salty breads (kaak, chips, crisps) | High | Substitute with whole grain unsalted bread |
| Kabsa, machboos (rice with meat) | Moderate-High | Reduce stock use; season with herbs/spices |
| Shawarma / fast food | Very High | Limit frequency; request no added sauce |
Major clinical challenge: 1+ billion Muslims fast — Ramadan creates significant BP variability through dehydration, meal timing, sleep disruption and stress.
- Once-daily morning medications: Shift to IFTAR (sunset meal) to maintain efficacy
- Long-acting formulations preferred (amlodipine, perindopril, olmesartan)
- Diuretics: Avoid or reduce dose during Ramadan fasting — volume depletion risk, especially in GCC summer heat
- ABPM during Ramadan recommended to assess BP pattern changes
- Encourage hydration during non-fasting hours (suhoor: pre-dawn meal)
- Advise against excessive salt at iftar and suhoor
- Patients with uncontrolled HTN, CKD, or on multiple agents: pre-Ramadan review advised
- Islamic scholars: exemption from fasting applies to those for whom fasting is genuinely harmful — educate patients about this
- Cost: Many GCC residents on self-pay or limited insurance — medication cost is a significant barrier
- Side effects not discussed openly — patients stop medications silently (especially ACEi cough, CCB oedema)
- Polypharmacy fatigue — patients with diabetes, hypertension and dyslipidaemia may take 5–8 tablets/day
- Cultural beliefs: "I feel fine, why do I need medication?" (asymptomatic nature of HTN)
- Lack of follow-up in fragmented health systems
- Suggestion of cure through traditional practices — patients discontinue medications
Nursing strategy: Use pill organisers, simplified dosing regimens, Morisky Medication Adherence Scale (MMAS-8), and motivational interviewing techniques.
| Practice | Evidence for BP | Risk |
|---|
| Cupping / Hijama | No evidence for BP reduction | Infection, haemorrhage, anticoagulation interaction |
| Black seed (Nigella sativa) | Small studies: modest BP effect | Drug interactions (warfarin); not proven in RCTs |
| Zamzam water | No clinical evidence | High sodium content in some preparations |
| Herbal remedies (Za'atar, fenugreek) | Insufficient evidence | Unknown interactions |
| Ruqyah / spiritual healing | Stress reduction possible benefit | Low risk; may delay medical care |
Cultural competency: Acknowledge traditional practices respectfully; emphasise that they do not replace evidence-based medication. Never dismiss cultural beliefs dismissively.
- DHA (Dubai Health Authority): HTN management protocols aligned with JNC8/ESC 2018
- MOH Saudi Arabia: National hypertension control programme; community screening vehicles
- HAAD / DOH Abu Dhabi: NCDs programme including HTN audit and quality indicators
- WHO HEARTS Technical Package: Being adopted across GCC for primary care HTN management
- Community screening programmes: Ramadan health camps, employer health checks, mall screening events
- Digital health: Seha app (UAE), Sehha app (UAE), Mawid (Saudi MOH) — BP tracking integration
- Arabic-language patient resources available via MOH Saudi, DHA, and Hamad Medical Corporation Qatar
- Nurses play a key role in follow-up clinics — Saudi Arabia and UAE have nurse-led HTN clinics in primary care
Screening Targets
- All adults >18 years
- Every 1 year if risk factors present
- Every 2–3 years if normotensive
- Opportunistic screening: every GP/clinic visit
High-Risk Groups (GCC)
- Age >40 years
- South Asian expats (genetic risk)
- Obese (BMI >30) — highly prevalent in GCC
- Diabetics (T2DM very prevalent)
- Positive family history
- Sedentary lifestyle / desk workers
Arabic Language Education
- Provide BP diary in Arabic
- Use Arabic infographics for DASH diet
- Bilingual medication cards
- Arabic-language BP monitoring videos
- Engage family during education sessions
- Use cultural analogies for BP explanations
Advanced Hypertension Nursing — GCC | ESC/AHA 2018 | DHA/MOH Aligned | For qualified healthcare professionals only | Always apply clinical judgement